PLEASANTON, CA--(Marketwire - August 06, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) announced the issuance of two key patents covering fundamental aspects of the Company’s Viral Immunotherapy platform. These two patents, 1) U.S. Patent No. 7,407,662 entitled, “Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content,” and 2) U.S. Patent No. 7,407,663, “Modified Immunodeficiency Virus Particles” cover the basic composition of viral particles resulting from Lipid Sciences’ proprietary viral delipidation process.
